Literature DB >> 15917111

Potency requirements of rabies vaccines administered intradermally using the Thai Red Cross regimen: investigation of the immunogenicity of serially diluted purified chick embryo cell rabies vaccine.

Jiri Beran1, Karel Honegr, Angelika Banzhoff, Claudius Malerczyk.   

Abstract

To determine the minimum vaccine potency per intradermal dose required to elicit an adequate immune response using the Thai Red Cross (TRC) regimen (2-2-2-0-1-1), healthy volunteers received 0.1 mL volumes of PCECV containing decreasing amounts of antigen. Subjects also received HRIG to evaluate potential interference with antibody production. Results indicated that when each 0.1 mL intradermal dose of PCECV contained antigen corresponding to 0.32 IU per intramuscular dose, every subject had titers above 0.5 IU/mL by day 14. These results confirm that the current World Health Organization (WHO) recommendations for vaccine potency (2.5 IU per intramuscular dose) are sufficient for use in the Thai Red Cross intradermal regimen.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15917111     DOI: 10.1016/j.vaccine.2005.03.007

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Assessing the relationship between antigenicity and immunogenicity of human rabies vaccines when administered by intradermal route: results of a metaanalysis.

Authors:  Mysore K Sudarshan; Bilagumba Gangaboraiah; Haradanahalli S Ravish; Doddabele H Ashwath Narayana
Journal:  Hum Vaccin       Date:  2010-07-01

2.  Generation and characterization of the human neutralizing antibody fragment Fab091 against rabies virus.

Authors:  Chen Li; Feng Zhang; Hong Lin; Zhong-can Wang; Xin-jian Liu; Zhen-qing Feng; Jin Zhu; Xiao-hong Guan
Journal:  Acta Pharmacol Sin       Date:  2011-01-31       Impact factor: 6.150

3.  Evaluation of a new five-injection, two-site,intradermal schedule for purified chick embryo cell rabies vaccine: A randomized, open-label, active-controlled trial in healthy adult volunteers in India.

Authors:  M K Sudarshan; S N Madhusudana; B J Mahendra; D H Ashwath Narayana; M S Ananda Giri; O Popova; H B Vakil
Journal:  Curr Ther Res Clin Exp       Date:  2005-07

4.  Reducing Cost of Rabies Post Exposure Prophylaxis: Experience of a Tertiary Care Hospital in Pakistan.

Authors:  Naseem Salahuddin; M Aftab Gohar; Naila Baig-Ansari
Journal:  PLoS Negl Trop Dis       Date:  2016-02-26

5.  Risk factors for inadequate antibody response to primary rabies vaccination in dogs under one year of age.

Authors:  Ryan M Wallace; Anna Pees; Jesse B Blanton; Susan M Moore
Journal:  PLoS Negl Trop Dis       Date:  2017-07-31

Review 6.  Challenges of Rabies Serology: Defining Context of Interpretation.

Authors:  Susan M Moore
Journal:  Viruses       Date:  2021-07-31       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.